精華製藥(002349.SZ)：上半年淨利同比降19.32%至1.04億元
格隆匯 8 月 30日丨精華製藥(002349.SZ)公佈半年報，報告期內，公司實現合併銷售收入6.07億元，同比下降4.66%，實現歸屬於母公司的淨利潤1.04億元，同比下降19.32%，經營活動產生的現金流量淨額1.23億元，同比增長85.20%。
公司控股子公司森萱醫藥於2020年6月24日通過了全國股轉公司掛牌委員會的審核，於2020年7月27日成功在新三板“精選層”公開發行股票並上市，成為新三板第一批精選層掛牌企業。扣除發行費用後森萱醫藥實際募集資金3.01億元併成功引入戰略投資者，改善了股本結構並提高了核心競爭力。同時，公司控股子公司金絲利藥業申請在全國中小企業股份轉讓系統(簡稱“新三板”)掛牌成功，於2020年4月1日起在全國股轉系統掛牌公開轉讓，證券簡稱：金絲利，證券代碼：873430，交易方式:集合競價交易，所屬層級:基礎層。通過深耕資本市場，在聚焦主業的同時逐步實現資產證券化。
在技術合作方面，公司與第二軍醫大學附屬長海醫院、美國哈佛大學、北京大學等知名高校、科研院所合作，對公司主要經典中成藥王氏保赤丸進行循證醫學與藥理及毒理作用的深入研究；與上海中醫藥大學、研究院等在戰略合作方向、技術研發層面就加強校企合作形成初步共識，將以大柴胡顆粒臨牀研究為切入點，全面推進校企合作；同時擬藉助上海中醫藥大學食品研發中心力量，在“王氏保赤粉”完成小試基礎上，進一步完善其保健功能的研究論證工作。
與南京中醫藥大學合作的中藥經典名方項目目前已完成處方中幾味藥材的基源鑑定、質量標準的制定等前期工作，後續將進行基準物質(中間體)及成品的試製工作。亳州保和堂、隴西保和堂着手開展藥食同源產品業務，食品類懷山藥、黨蔘、黃芪等將加快推入市場。季德勝科技完成了季德勝爽膚水2個單品的研發、檢測、備案及試生產工作以及季德勝凝膠及面膜的基礎性研發。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
